Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
M.D. Anderson Cancer Center
Exelixis
Compugen Ltd
Memorial Sloan Kettering Cancer Center
Compugen Ltd
Incyte Corporation